Related Experiment Video
Updated: Jun 8, 2026

Application of Bedside Lower Extremity Rehabilitation Robots in Stroke Rehabilitation: A Randomized Controlled Trial
Published on: November 28, 2025
Poor effect of guideline based treatment of restless legs syndrome in clinical practice
Jana Godau1, Nike Spinnler, Anne-Kathrin Wevers
1Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and Centre of Neurology, University of Tübingen, Germany. jana.godau@medizin.uni-tuebingen.de
Background:
Numerous randomised controlled trials have proved the efficacy of dopaminergic and non-dopaminergic drugs in the treatment of restless legs syndrome (RLS). In contrast, epidemiological data demonstrate generally insufficient RLS treatment in clinical practice.
Objective:
To prospectively assess the success of RLS treatment in the clinical setting and to evaluate potential demographic factors and comorbidities that may influence the response to therapy.
Methods:
100 patients with idiopathic RLS (40% had never received RLS specific treatment before) were examined at baseline and after 12 months. Recommendations for therapy according to RLS treatment guidelines of the German Neurological Society were given at baseline. Primary measures for the success of therapy were reduction of RLS symptoms (IRLS) and improvement of quality of life (RLS-QoL).
Results:
No statistically significant improvement of IRLS or RLS-QoL was detected after 12 months, in initially untreated or in pretreated patients. Poor treatment success, regarding improvement of RLS symptoms, quality of life and number of RLS related physician contacts was related to the presence of neuropsychiatric comorbidity--that is, somatoform disorders (prevalence 41%), chronic pain (32%), anxiety (20%) and major depression (16%).
Conclusion:
Success of guideline based treatment of RLS appears to be rather poor in clinical practice. Neuropsychiatric comorbidity may be a target for interventions to improve overall outcome.
Related Concept Videos
Restless Leg Syndrome and Night Terrors
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
REM Sleep Behavior Disorder
RBD is significantly associated with...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Alterations in Muscle Tone lll